All News
Filter News
Found 808,979 articles
-
Oligonucleotide Synthesis Market Valuation Worth USD 9.91 Billion By 2027 | Emergen Research
6/1/2022
Increasing prevalence of various genetic disorders, chronic diseases and viral infections, rising research based activities in pharmaceutical and biotechnology companies, and increasing applications of synthesized oligonucleotides are some key factors expected to drive global market growth.
-
Occlusion Devices Market Valuation Worth USD 4,378.5 Million in 2027 | Emergen Research
6/1/2022
Increasing number of surgeries, rising number of emergency, trauma and accident cases, and high prevalence of various chronic diseases are some key factors expected to drive global market growth.
-
Neurostimulation Devices Market Valuation Worth USD 13.70 Billion in 2027 | Emergen Research
6/1/2022
Increasing prevalence of neurological diseases, gastroparesis, urinary and fecal incontinence, growing demand for minimally invasive surgeries, and improving healthcare infrastructure are some key factors expected to drive global market growth.
-
Nerve Repair and Regeneration Market Valuation Worth USD 11.62 Billion in 2027 | Emergen Research
6/1/2022
Increasing prevalence neurodegenerative disorders, rising geriatric population, and high focus on developing advanced nerve repair and regeneration devices are some factors expected to drive global market growth.
-
Medical Devices Testing Services Market Valuation Worth USD 14.25 Billion in 2027 | Emergen Research
6/1/2022
Increasing incidence of various chronic diseases across the globe, growing demand for in-vitro tests, and rising focus on developing advanced medical devices testing services are some key factors expected to drive global market growth.
-
Digital Biomarkers Market Valuation Worth USD 10.38 billion in 2027 | Emergen Research
6/1/2022
Rising incidence of various chronic disorders and infectious diseases across the globe, increasing adoption of hand held and wearable digital devices, and rapid development in IT and telecommunication sector are some key factors expected to drive global market growth.
-
Clinical Perinatal Software Market Valuation Worth 393.3 Million in 2027 | Emergen Research
6/1/2022
Rising birth rate across the globe, rapid technological upgrades in the perinatal software, and increasing government initiatives to promote clinical perinatal software and tools are some key factors expected to drive global market revenue growth.
-
Cardiac Monitoring & Cardiac Rhythm Management Devices Market Valuation Worth USD 29.32 Billion in 2027 | Emergen Research
6/1/2022
Rising prevalence of cardiovascular diseases across the globe, rapid advancements in cardiac monitoring and cardiac rhythm management technology, and increasing R&D investments are some key factors expected to drive global market growth.
-
3D Printing Healthcare Market Valuation Worth USD 4,070.8 Million in 2027 | Emergen Research
6/1/2022
Increasing prevalence of cardiovascular diseases and orthopedic disorders worldwide, rising demand for contact lenses, dental implants, hearing aids, and prosthetics, increasing geriatric population, and rapid advancements in 3D printing are some key factors expected to drive global market growth.
-
GSK announced that it is acquiring Affinivax for up to $3.3 billion to gain its novel class of developmental vaccines and its MAPS technology.
-
How much could a human genome cost? The answer is $100, according to newly launched biotech company Ultima Genomics, which received $600 million in backing.
-
Eledon Pharmaceuticals announced positive topline results from its Phase IIa clinical trial evaluating tegoprubart in patients with amyotrophic lateral sclerosis (ALS).
-
The ASCO Annual Meeting being held in June 3 to 7 will introduce hundreds of posters, abstracts and presentations of cancer studies, preclinical and clinical. BioSpace looks at three presenters.
-
The long weekend saw BMS's Opdivo, Novartis's Kymriah and Roche's Evrysdi win FDA approvals in new indications.
-
Although there are many mechanisms proposed that contribute to neuroinflammation and damage caused by inflammaging in the brain, INmune Bio has focused on tumor necrosis factor (TNF).
-
BioMarin Delays Hemophilia A Therapy Valoctocogene Roxaparvovec Filing as FDA Calls for More Data
5/31/2022
The U.S. FDA has requested some additional data from BioMarin Pharmaceuticals for the BLA it filed for the hemophilia A therapy valoctocogene roxaparvovec. -
The FDA has decided to extend the Prescription Drug User Fee Act (PDUFA) review date for TG Therapeutics’s ublituximab until December 2022.
-
The WHO reports it’s too early to tell if the monkeypox outbreak could become a pandemic, but believe there is a window of opportunity to control the cases.
-
RhoVac AB announced Tuesday that its candidate therapeutic for prostate cancer failed to meet targets in a Phase IIb study.
-
The initiative, a partnership between non-profit biotech company n-Lorem and Columbia University, focuses on developing personalized experimental ASO medicines for nano-rare ALS patients.